To estimate the relative efficiency of transmission of different HIV-1 drug-resistance mutations from patients failing treatment, considered as potential transmitters (PTs), to seroconverters (SCs).
Design
Ecological cross-sectional study.
Methods
HIV-1 protease and reverse transcriptase (RT) sequence data, obtained from 155 SCs and 2,690 PTs at the Department of Molecular Biology of the University of Siena, Italy, in the period 1997–2004 were used. The efficiency of transmission was studied by odds ratio (OR) analysis and evaluation of 95% confidence intervals (95% CIs). For mutations not detected in viruses from SCs, a binomial probability model was used, assuming P-values <0.05 as indicative of a negative selection at transmission.
Results
The overall prevalence of drug mutations associated with nucleoside reverse transcriptase inhibitors (NRTIs), non-NRTIs (NNRTIs) and protease inhibitors (PIs) was 13.2%, 4.6% and 2.0% in SCs, and 69.9%, 27.6% and 33.7% in PTs, respectively. Among RT mutations present both in PTs and SCs, M184I/V and T215F/Y had the lowest relative efficiency of transmission, whereas V118I, Y181C/I and K219E/Q showed the highest relative efficiency. Of the three major protease mutations that could be evaluated by this approach, M46I/L had a lower rate of transmission than I84V and L90M. Among the mutations not detected in viruses from SCs, the RT E44D, V108I, Q151M and Y188C/H/L, and the protease D30N, G48V and V82A/F/S/T substitutions appeared to be negatively selected.
Conclusions
The transmission rate of drug-resistant HIV-1 variants may be differentially affected by the mutational pattern. The binomial model enabled to evaluate the negative selection against specific substitutions. Given the low prevalence of some resistance mutations in SCs, very large data sets are required to evaluate the potential selection of such mutations.
References
1.
MocroftA., VellaS., BenfieldT.L.Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group.Lancet1998; 352: 1725–1730.
2.
RichmanD.D., MortonS.C., WrinT.The prevalence of antiretroviral drug resistance in the United States.AIDS2004; 18: 1393–1401.
3.
TamaletC., FantiniJ., TourresC., & YahiN.Resistance of HIV-1 to multiple antiretroviral drugs in France: a 6-year survey (1997–2002) based on an analysis of over 7000 genotypes.AIDS2003; 17: 2383–2388.
4.
ScottP., ArnoldE., EvansB.Surveillance of HIV antiretroviral drug resistance in treated individuals in England: 1998–2000.J Antimicrob Chemother2004; 53: 469–473.
5.
ZazziM., RomanoL., RazzoliniF.Prevalence and time trends of primary and secondary antiretroviral drug resistance in a large sequence database maintained at the University of Siena, Italy.2nd European HIV Drug Workshop. 11–13 March 2004, Rome, Italy. Abstract 65.
6.
LittleS.J., HolteS., RoutyJ.P.Antiretroviral-drug resistance among patients recently infected with HIV.N Engl J Med2002; 347: 385–394.
7.
GrantR.M., HechtF.M., WarmerdamM.Time trends in primary HIV-1 drug resistance among recently infected persons.JAMA2002; 288: 181–188.
8.
TurnerD., BrennerB., RoutyJ.P.Diminished representation of HIV-1 variants containing select drug resistance-conferring mutations in primary HIV-1 infection.J Acquir Immune Defic Syndr2004; 37: 1627–1631.
UK Collaborative Group on Monitoring the Transmission of HIV Drug Resistance.Analysis of prevalence of HIV-1 drug resistance in primary infections in the United Kingdom.Br Med J2001; 322: 1087–1088.
11.
de MendozaC., RodriguezC., CorralA., del RomeroJ., GallegoO., SorianoV.Evidence for differences in sexual transmission efficiency of HIV strains with distinct drug resistance genotypes.Clin Infect Dis2004; 39: 1231–1238.
12.
ViolinM., VellecaR., Cozzi-LepriA.Prevalence of HIV-1 primary drug resistance in seroconverters of the ICoNA Cohort over the period 1996–2001.J Acquir Immune Defic Syndr2004; 36: 761–764.
13.
QuinnT.C., WawerM.J., SewankamboN.Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group.N Engl J Med2000; 342: 921–929.
14.
CohenM.S.Sexually transmitted diseases enhance HIV transmission: no longer a hypothesis.Lancet1998; 35 Suppl 3: 5–7.
15.
KatzensteinT.L., Eugen-OlsenJ., HofmannB.HIV-infected individuals with the CCR delta32/CCR5 genotype have lower HIV RNA levels and higher CD4 cell counts in the early years of the infection than do patients with the wild type. Copenhagen AIDS Cohort Study Group.J Acquir Immune Defic Syndr Hum Retrovirol1997; 16: 10–14.
16.
PeduzziC., PierottiP., VenturiG., RomanoL., MazzottaF., ZazziM.Performance of an in-house genotypic antiretroviral resistance assay in patients pretreated with multiple human immunodeficiency virus type 1 protease and reverse transcriptase inhibitors.J Clin Virol2002; 25: 57–62.
17.
JohnsonV.A., Brun-VezinetF., ClotetB.Update of the Drug Resistance Mutations in HIV-1: 2005.Top HIV Med2005; 13: 51–57.
18.
BlowerS.M., AschenbachA.N., GershengornH.B., KahnJ.O.Predicting the unpredictable: transmission of drug-resistant HIV.Nat Med2001; 7: 1016–1020.
19.
YerlyS., RakikA., De LoesS.K.Switch to unusual amino acids at codon 215 of the human immunodeficiency virus type 1 reverse transcriptase gene in seroconvertors infected with zidovudine-resistant variants.J Virol1998; 72: 3520–3523.
20.
Garcia-LermaJ.G., NidthaS., BlumoffK., WeinstockH., HeneineW.Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons.Proc Natl Acad Sci USA2001; 98: 13907–13912.
21.
ViolinM., Cozzi-LepriA., VellecaR.Risk of failure in patients with 215 HIV-1 revertants starting their first thymidine analog-containing highly active antiretroviral therapy.AIDS2004; 18: 227–235.
22.
SuligoiB., PezzottiP., BorosS., UrciuoliR., RezzaG.The HIV Study Group. Epidemiological changes in AIDS and HIV infection in Italy.Scand J Infect Dis Suppl2003; 35 Suppl 106: 12–16.
